Patents Represented by Attorney Charles W. Ashbrook

Find this attorney in the Justia Lawyer Directory

  • Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
    Patent number: 6166052
    Abstract: The present invention provides compounds that block calcium channels having the Formula I shown below. ##STR1## The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, asthma, amyotropic lateral sclerosis, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: December 26, 2000
    Assignee: Warner-Lambert Company
    Inventors: Lain-Yen Hu, Michael Francis Rafferty, Todd Robert Ryder, Anthony Denver Sercel, Yuntao Song
  • Benzenesulfonamide inhibitors of PDE-IV and their therapeutic use
    Patent number: 6162830
    Abstract: The present invention provides compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of diseases whose treatment benefits from the inhibition of phosphodiesterase (PDE-IV) or Tumor Necrosis Factor (TNF) including asthma, allergic diseases, rheumatoid arthritis, osteoarthritis, septic shock. The compounds provided by this invention have formula (I) wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 are as defined herein.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: December 19, 2000
    Assignee: Warner-Lambert Company
    Inventors: David Thomas Connor, Joseph Peter Menetski
  • Sulfonamide inhibitors of matrix metalloproteinases
    Patent number: 6153612
    Abstract: Sulfonamide compounds are described which are inhibitors of matrix metalloproteinases, particularly stromelysin-1 and gelatinase A (72 kD gelatinase). Also described are methods for the treatment of multiple sclerosis, atherosclerotic plaque rupture, aortic aneurism, heart failure, restenosis, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, arthritis, or other autoimmune or inflammatory disorders dependent upon tissue invasion by leukocytes using the compounds.
    Type: Grant
    Filed: October 5, 1999
    Date of Patent: November 28, 2000
    Assignee: Warner-Lambert Company
    Inventors: Daniel F. Ortwine, Claude F. Purchase, Jr., Andrew D. White
  • Naphthyridinones for inhibiting protein tyrosine kinase and cell cycle kinase mediated cellular proliferation
    Patent number: 6150359
    Abstract: This invention relates to the inhibition of protein tyrosine kinase (PTK) and cell cycle kinase mediated cellular proliferation. More specifically, this invention relates to naphthyridinones and their use in inhibiting cellular proliferation and PTK or cell cycle kinase enzymatic activity.
    Type: Grant
    Filed: January 26, 2000
    Date of Patent: November 21, 2000
    Assignee: Warner-Lambert Company
    Inventors: Mark Robert Barvian, William Alexander Denny, Ellen Myra Dobrusin, James Marino Hamby, Howard Daniel Hollis Showalter, Andrew Mark Thompson, Roy Thomas Winters, Zhipei Wu
  • Benzopyranone and quinolone inhibitors of ras farnesyl transferase
    Patent number: 6143766
    Abstract: The present invention provides ras farnesyl transferase inhibiting compounds of Formula I ##STR1## The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula I.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: November 7, 2000
    Assignee: Warner-Lambert Company
    Inventors: James Stanley Kaltenbronn, Daniele Marie Leonard, Joseph Thomas Repine
  • Compounds inhibiting the association of the PDGF receptor and phosphatidylinositol 3-kinase and their use
    Patent number: 6136798
    Abstract: The present invention provides compounds that inhibit the association of platelet-derived growth factor and phosphatidylinositol 3-kinase. The present invention also provides pharmaceutical compositions that contain a compound that inhibits the association of platelet-derived growth factor and phosphatidylinosital 3-kinase, and methods of treating cancer, restenosis, arthritis, dermatitis, atherosclerosis, vein graft intimal hyperplasia, neointimal hyperplasia of vascular smooth muscle and psoriasis using compounds that inhibit the association of platelet-derived growth factor and phosphatidylinositol 3-kinase.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: October 24, 2000
    Assignee: Warner-Lambert Company
    Inventors: Wayne Livingston Cody, Annette Marian Doherty, Scott R. Eaton, Robert Lee Panek
  • Isothiazolones and pharmaceutical formulations
    Patent number: 6133270
    Abstract: Isothiazolones having the general structure ##STR1## where A is a monocyclic or bicyclic ring which may contain up to 3 heteroatoms selected from O, S, and N; R.sup.1 and R.sup.2 are substituent groups such as alkyl, alkoxy, hydroxy, nitro, cyano, amino, and carboxy; and R.sup.5 is alkyl, cycloalkyl, phenyl, and Het. The isothiazolones are useful as anti-retroviral agents, anti-inflammatory agents, and anti-atherosclerotic agents.
    Type: Grant
    Filed: June 26, 1997
    Date of Patent: October 17, 2000
    Assignee: Warner-Lambert Company
    Inventors: Gary Louis Bolton, John Michael Domagala, Edward Faith Elslager, Rocco Dean Gogliotti, Terri Stoeber Purchase, Joseph Peter Sanchez, Bharat Kalidas Trivedi
  • ACE inhibitor-MMP inhibitor combinations
    Patent number: 6133304
    Abstract: The present invention relates to compositions comprising a compound which inhibits the actions of angiotensin-converting enzyme and a compound which inhibits the actions of matrix metalloproteinase enzymes and the use of such compositions for treating ventricular dilation, heart failure and cardiovascular fibrotic pathologies.
    Type: Grant
    Filed: February 7, 2000
    Date of Patent: October 17, 2000
    Assignee: Warner-Lambert Company
    Inventors: Joseph Thomas Peterson, Jr., Milton Lethan Pressler
  • Bicyclic inhibitors of protein farnesyl transferase
    Patent number: 6133303
    Abstract: The present invention provides compounds of Formula (I). The present invention also provides a method of treating cancer and treating or preventing restenosis or atherosclerosis. Also provided by the present invention is a pharmaceutically acceptable composition containing a compound of Formula (I).
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: October 17, 2000
    Assignee: Warner-Lambert Company
    Inventors: Jack Bikker, Ellen Myra Dobrusin, Annette Marian Doherty, Matthew Drowns, James Stanley Kaltenbronn, Juergen Kleinschroth, Dennis Joseph McNamara, John Quin, III, Joseph Thomas Repine, Marcin Stasiak
  • Use of thiazolidinedione derivatives in the treatment of insulin resistance
    Patent number: 6130216
    Abstract: The present invention provides methods of using thiazolidinedione in the treatment of insulin resistance.
    Type: Grant
    Filed: November 16, 1999
    Date of Patent: October 10, 2000
    Assignee: Warner-Lambert Company
    Inventors: Tammy Antonucci, Dean Lockwood, Rebecca Norris
  • GABA analogs to prevent and treat gastrointestinal damage
    Patent number: 6127418
    Abstract: The present invention is directed to a method for preventing visceral and gastrointestinal damage such as gastric ulcers by administering a gamma-aminobutyric acid (GABA) analog and for treating gastrointestinal diseases such as inflammatory bowel disorders (IBD), functional bowel disorders (FBD) including dyspepsia and other visceral pain.
    Type: Grant
    Filed: April 19, 1999
    Date of Patent: October 3, 2000
    Assignee: Warner-Lambert Company
    Inventors: Lionel Bueno, Maria Chovet, Laurent Diop, Antonio Guglietta, Hilary J. Little, Michael Francis Rafferty, Jiayuan Ren, Charles Price Taylor, Jr., William P. Watson
  • Irreversible inhibitors of tyrosine kinases
    Patent number: 6127374
    Abstract: This invention provides irreversible inhibitors of tyrosine kinases having for formula ##STR1## which compounds are useful for treating cancer, restenosis, atherosclerosis, endometriosis and psoriasis.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: October 3, 2000
    Assignee: Warner-Lambert Company
    Inventor: Alexander James Bridges
  • Pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors
    Patent number: 6124291
    Abstract: This invention relates to pyrrolo[1,2-a]pyrazine-1,4-diones of general formula: ##STR1## wherein B is carbonyl or methylene, R.sup.2, R.sup.4, R.sup.5, and R.sup.6 are hydrogen, alkyl, or substituted alkyl, A is a basic group, and Q is hydrogen or a keto heterocycle group.The compounds are inhibitors of serine proteases, typically thrombin, Factor Xa, and Factor VIIa, and are useful for treating and preventing thrombotic disorders.
    Type: Grant
    Filed: October 27, 1998
    Date of Patent: September 26, 2000
    Assignee: Warner-Lambert Company
    Inventors: Kent A. Berryman, Annette M. Doherty, Jeremy J. Edmunds, M. Arshad Siddiqui
  • Process for the preparation of (+/-)3-(3,4-dichlorophenyl)-2-dimethylamino-2-methylpropan-1-OL or cericlamine (INN)
    Patent number: 6121491
    Abstract: Process for the preparation of cericlamine which consists: i) in arylating methacrylic acid with the diazonium chloride of 3,4-dichloroaniline, to obtain (+/-)2-chloro-3-(3,4-dichlorophenyl)-2-methylpropionic acid, ii) in aminating the acid with dimethylamine, to obtain (+/-)3-(3,4-dichlorophenyl)-2-dimethylamino-2-methylpropionic acid, or an alkaline metal salt thereof, iii) in esterifying the amino-acid or its salt, then, iv) in reducing the ester by a metal or organometal hydride to obtain (+/-)3-(3,4-dichlorophenyl)-2-dimethylamino-2-methyl-propan-1-ol.
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: September 19, 2000
    Assignee: Warner-Lambert Company
    Inventors: Marc Nicolas, Blandine Laboue, Dominique Depernet
  • Substituted peptidylamine calcium channel blockers
    Patent number: 6117841
    Abstract: The present invention provides compounds that block calcium channels having the Formula I shown below. ##STR1## The present invention also provides methods of using the compounds of Formula I to treat stroke, cerebral ischemia, head trauma, or epilepsy and to pharmaceutical compositions that contain the compounds of Formula I.
    Type: Grant
    Filed: January 19, 1999
    Date of Patent: September 12, 2000
    Assignee: Warner-Lambert Company
    Inventors: Lain-Yen Hu, Thomas Charles Malone, Laszlo Nadasdi, Michael Francis Rafferty, Todd Robert Ryder, Diego F. Silva, Yuntao Song, Balazs G. Szoke, Laszlo Urge
  • Compounds for and methods of inhibiting matrix metalloproteinases
    Patent number: 6117869
    Abstract: The present invention relates to compounds of Formula I that inhibit matrix metalloproteinases and to a method of inhibiting matrix metalloproteinases using the compounds ##STR1## More particularly, the present invention relates to a method of treating diseases in which matrix metalloproteinases are involved such as multiple sclerosis, atherosclerotic plaque rupture, restenosis, aortic aneurysm, heart failure, periodontal disease, corneal ulceration, burns, decubital ulcers, chronic ulcers or wounds, cancer metastasis, tumor angiogenesis, osteoporosis, rheumatoid or osteoarthritis, renal disease, left ventricular dilatation, or other autoimmune or inflammatory diseases dependent upon tissue invasion by leukocytes.
    Type: Grant
    Filed: July 26, 1999
    Date of Patent: September 12, 2000
    Assignee: Warner-Lambert Company
    Inventors: Joseph Armand Picard, Bruce David Roth, Drago Robert Sliskovic
  • Dopamine D4 receptor antagonists
    Patent number: 6087364
    Abstract: Compounds that are antagonists of dopamine D4 receptors, methods of treating psychosis and schizophrenia using the compounds, and pharmaceutically acceptable compositions that contain the dopamine D4 receptor antagonists are disclosed.
    Type: Grant
    Filed: January 29, 1998
    Date of Patent: July 11, 2000
    Assignee: Warner-Lambert Company
    Inventors: Thomas Richard Belliotti, David Juergen Wustrow
  • Sulfonamide substituted aspartic acid interleukin-1.beta. converting enzyme inhibitors
    Patent number: 6083981
    Abstract: The present invention relates to compounds that are inhibitors of interleukin-1.beta. converting enzyme that have the Formula I, II, or III. ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1.beta. converting enzyme.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: July 4, 2000
    Assignee: Warner-Lambert Company
    Inventors: Hamish John Allen, Kenneth Dale Brady, William Glen Harter, Elizabeth Ann Lunney, Mark Stephen Plummer, Tomi Sawyer, Aurash Shahripour, Nigel Walker
  • Substituted furanones, compositions and antiarthritic use
    Patent number: 6066667
    Abstract: The invention provides substituted furanone antiarthritic and analgesic pharmaceutical agents defined by Formula I, ##STR1## wherein: R.sup.1 is selected from the group consisting of(a) S(O).sub.2 CH.sub.3,(b) S(O).sub.2 NH.sub.2,(c) S(O).sub.2 NHC(O)CF.sub.3,(d) S(O)(NH)CH.sub.3,(e) S(O)(NH)NH.sub.2,(f) S(O)(NH)NHC(O)CF.sub.3,(g) P(O)(CH.sub.3)OH, and(h) P(O)(CH.sub.3)NH.sub.2 ;R.sup.2 and R.sup.3 independently are selected from(1) hydrogen,(2) halo,(3) C.sub.1 -C.sub.6 alkyl,(4) C.sub.1 -C.sub.6 alkoxy, and(5) C.sub.1 -C.sub.6 alkylthio;n is an integer from 1 to 3;m is an integor from 1 to 3;or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 17, 1999
    Date of Patent: May 23, 2000
    Inventor: Charles D. Ashbrook
  • Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
    Patent number: 6046222
    Abstract: Novel methods of using thiazolidinone derivatives and related antihyperglycemic agents to treat populations at risk for developing noninsulin-dependent diabetes mellitus (NIDDM) and complications arising therefrom are disclosed. In one embodiment, the compounds of the invention are used to treat polycystic ovary syndrome in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus. In another embodiment, the compounds of the invention are used to treat gestational diabetes in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus.
    Type: Grant
    Filed: June 4, 1997
    Date of Patent: April 4, 2000
    Assignee: Warner-Lambert Company
    Inventors: Tammy Antonucci, Dean Lockwood, Rebecca Norris